This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Biontech Ag, Ganymed Pharmaceuticals Ag, Ganymed Pharmaceuticals Gmbh. Active years: 2018-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 37 
1 out of 51 
1 out of 10 Years Active: 2018-2020
Title: Hayat Bähr-Mahmud: Innovator in Cancer Treatment
Introduction
Hayat Bähr-Mahmud is a notable inventor based in Wiesbaden, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and development of binding agents.
Latest Patents
Hayat Bähr-Mahmud holds 1 patent for his invention titled "Agents for treatment of claudin expressing cancer diseases." This patent provides binding agents that contain a binding domain specific for CD3, allowing interaction with T cells, and a binding domain specific for a tumor-associated claudin molecule. The methods described in this patent are aimed at treating cancer effectively.
Career Highlights
Throughout his career, Hayat has worked with prominent companies in the biotechnology sector, including BioNTech AG and Ganymed Pharmaceuticals GmbH. His work in these organizations has contributed to advancements in cancer therapies and immunotherapy.
Collaborations
Hayat has collaborated with esteemed colleagues, including Ugur Sahin and Özlem Türeci, who are also recognized for their contributions to cancer research and treatment.
Conclusion
Hayat Bähr-Mahmud's innovative work in developing targeted cancer treatments showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his patent reflects the potential for significant impact in this field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile